
Psoriasis
Latest News
Video Series

Latest Videos
Shorts










More News

Experts outline how to recognize undertreated psoriasis, assess incomplete response, and make individualized decisions when escalating therapy.

ORKA-001 achieved PASI 100 in 61% of high-dose patients at week 16 in the phase 2b EVERLAST-B trial of moderate-to-severe psoriasis.

Tina Bhutani-Jacques, MD, explored how disease location, prior treatment response, and patient preference shape topical treatment decisions across 3 plaque psoriasis cases.

Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.

In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations above 3 times the upper limit of normal.

Patients with plaque psoriasis treated with roflumilast cream or foam reported greater improvements in sexual function and relationships vs vehicle, including those with genital involvement at baseline.

By week 36, combination therapy altered 482 proteins and 467 genes vs 140 and 16 with ixekizumab alone in exploratory TOGETHER-PsO data.

At 2 years, 70% of patients on oral icotrokinra for scalp, genital, or hand/foot psoriasis had clear or almost clear skin, with no new safety signals.

Phase 3 LATITUDE Atlas data presented at EADV 2026 showed higher rates of complete and near-complete skin clearance with zasocitinib compared with deucravacitinib.

The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.

Week 28 data from the phase 2a EVERLAST-A trial showed PASI 100 responses increased to 71.4% despite no additional ORKA-001 dosing after week 4.

Takeda’s investigational oral TYK2 inhibitor is supported by phase 3 LATITUDE data demonstrating significant skin clearance versus placebo and apremilast.

In a 52-week open-label trial, tildrakizumab-asmn (Ilumya) reduced a mortality-linked DNA methylation clock by up to 0.5 years while clearing psoriasis symptoms.

Post hoc RESOLVE analysis shows that patients weighing at least 100 kg experience slower clinical response rates to brodalumab than those under 100 kg, establishing body weight over BMI as a key predictor of treatment timing.

Real-world cohort research links psoriasis biologics to notably fewer heart attacks and strokes over 10 years, with benefits across drug classes and races.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
















